lilly zepbound weight loss news

Eli Lilly shares drop

Lilly forecasts weak fourth-quarter sales of weight-loss drug, shares slump

Eli Lilly forecast sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street estimates in the fourth quarter, sending the drugmaker's shares down more than 8% on Tuesday.

MarketWatch · 21h

Eli Lilly’s stock falls as weight-loss drug sales disappoint

Shares of Eli Lilly and Co. slipped 0.4% in premarket trading Tuesday, after the drug maker provided a disappointing fourth-quarter revenue outlook, citing slower-than-expected growth in sales of its weight-loss drugs.

CNBC on MSN · 19h

Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand

Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity and diabetes drugs.

Reuters · 12d

Lilly asks to join lawsuit over compounded versions of its weight-loss drugs

Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug Administration over the agency's decision that Lilly's blockbuster weight-loss and diabetes drugs are no longer in short supply.

17h

Maker of weight-loss drugs to ask Trump to pause price negotiations: Report

Eli Lilly and other drugmakers are reportedly planning to urge the Trump administration to pause Medicare drug-price ...

13d

Lilly’s Obesity Drug Zepbound To Be Key 2025 Health Cost Driver

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...

FDA Approves Weight-loss Drug Zepbound For Sleep Apnea – Will Insurance Cover This $1000-Per-Month Medication?

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...

Becker's Hospital Review18h

New weight loss pill to be approved by early 2026: Eli Lilly

Eli Lilly expects its experimental weight loss pill, orforglipron, to receive approval as early as next year, CEO David Ricks told Bloomberg Jan. 13, according to a Wall Street Journal report.

FierceBiotech1d

Kailera reports Zepbound-rivaling weight loss in phase 2 obesity trial

Fresh from a $400 million series A round, Kailera Therapeutics has shown off phase 2 data on an obesity candidate it believes ...

4don MSN

Eli Lilly's Zepbound Can Now Be Covered by Medicare to Treat Sleep Apnea

Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and ...

7hon MSN

Pennsylvania woman speaks out after Independence Blue Cross drops weight loss drug coverage

A Bucks County woman is speaking out after her insurance company decided to no longer cover weight loss drugs.

6don MSN

Medicare can now cover Eli Lilly's Zepbound for sleep apnea, Health Department agency says

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...

Ibj.com1d

Lilly sees new weight-loss pill approval in early 2026, CEO says

Pills would be more convenient for patients and also easier to manufacture at large scale than other top weight-loss drugs, which require , CEO Dave Ricks said.

20hon MSN

Lilly forecasts weak sales of weight-loss drug in fourth quarter

Eli Lilly expects sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street ...

14hon MSN

Eli Lilly’s Zepbound and Mounjaro Sales Missed Estimates Again. The Wobble’s Looking Serious.

The results are an uncomfortable echo of late October 2024, when Mounjaro and Zepbound missed by similar margins. Those ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results